
WALD Stock Forecast & Price Target
WALD Analyst Ratings
Bulls say
Waldencast is showing positive signs of growth, with a recent partnership and debt repayment strengthening their balance sheet. While fourth quarter sales and Adjusted EBITDA were below expectations, the company's gross margin continues to remain strong and their reliance on a single distributor for Obagi in the U.S. is a potential risk. Additionally, an ongoing SEC investigation and a slowing beauty market could impact their growth plans, while inflation and concentrated share ownership may add pressure to expenses and decision-making processes.
Bears say
Waldencast is facing several challenges that contributed to its negative outlook, including declining revenue in its Milk Makeup segment and a delayed strategic review that brings uncertainty to its future plans. Additionally, the company's high costs related to an ongoing SEC investigation and investments in new product launches will likely put pressure on its profitability and limit potential growth. As a result of these factors, the financial analyst is skeptical of Waldencast's ability to maximize shareholder value and has lowered their outlook for the company's future earnings.
This aggregate rating is based on analysts' research of Waldencast Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
WALD Analyst Forecast & Price Prediction
Start investing in WALD
Order type
Buy in
Order amount
Est. shares
0 shares